ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Trastuzumab is on this study

  • The record lists it as a treatment.
  • Claude Opus 5.5 judged it a tool of the study (an imaging tracer, a test of drug response). Nov 2, 2026, 3:40 AM UTC“Radiolabelled as a PET tracer beside T-DM1”
  • The role rule said “Tested”; the reading replaced it.
  • So Trastuzumab's page lists this study under “As a tool”.
3 links0 made here, not in the record6 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govReplaced, or read an older version
Oct 19Oct 26Nov 2Nov 9Nov 16Nov 23TodayNCT02226276Copper Cu64-DOTA-Trastuzumab PET inPredicting Response toTreatment WithAdo-Trastuzumab Emtansinein Patients With MetastaticHER2 Positive Breast CancerCity of Hope Medical CenterNA · active not recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 3 · ClinicalTrials.gov record · Version of 2026-11-03Version of 2026-11-03CONDITIONSBreast NeoplasmsThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSTrastuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · ProcedureNov 18 · Rule based · TestedProcedureAdo-Trastuzumab EmtansineIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 10 · Claude Opus 5.5 · Background · careNov 18 · Rule based · TestedBackground · care

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
1 version of the record seen on ClinicalTrials.gov, Nov 3 · changes seen, not judgments
Nov 2TrastuzumabClaude Opus 5.5ProcedureCurrent
Nov 2Ado-Trastuzumab EmtansineClaude Opus 5.5TestedReplaced
Nov 10Ado-Trastuzumab EmtansineClaude Opus 5.5Background · careCurrent
Nov 18TrastuzumabRule based · role ruleTestedOverridden
Nov 18Ado-Trastuzumab EmtansineRule based · role ruleTestedOverridden
As of nowBreast NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.